MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
CAPR stock logo

CAPR

Capricor Therapeutics, Inc.

$7.1
0.09
 (1.21%)
Exchange:   NASDAQ
Market Cap:   324.591M
Shares Outstanding:  
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Linda MarbΓ‘n
Full Time Employees:  160
Address: 
10865 Road to the Cure
San Diego
CA
92121
US
Website:  https://www.capricor.com
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Click to read more…

Revenue Segmentation

πŸ”’ You are currently logged out

Login

EPS

πŸ”’ You are currently logged out

Login
View full analyst estimates

Earnings Call

πŸ”’ You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Current Key Metrics

πŸ”’ You are currently logged out

Login

Forward P/E Ratios

πŸ”’ You are currently logged out

Login

SWOT Analysis

πŸ”’ You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator

πŸ”’ Premium Feature

Log in to access the CAPR Intrinsic Value Calculator

πŸ”‘ Log In
πŸ“ Sign Up Free

Get comprehensive stock analysis with premium features

πŸ”’ You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news

22-08-2025 16:41
Capricor Therapeutics, Inc. Sued for Securities Law Violations – Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights – CAPR
21-08-2025 10:38
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
18-08-2025 18:46
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
18-08-2025 17:57
Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion
06-08-2025 18:00
Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm
06-08-2025 10:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. – CAPR